Ocugen is trading 5.2% down now at $1.35 amid a weak biotech tape and broader risk-off sentiment.
- Shares are likely drifting lower following prior dilution-related offerings and an earnings-driven pullback.
- Traders are reducing exposure to smaller-cap biotech as major indices and the XBI sector decline.
- There are no fresh company-specific headlines or catalysts reported today.